Drugs that contain Brimonidine Tartrate; Brinzolamide
1. Simbrinza patents expiration
SIMBRINZA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6316441 | ALCON LABS INC | Brinzolamide and brimonidine for treating glaucoma |
Dec, 2019
(4 years ago) | |
| US9421265 | ALCON LABS INC | Aqueous pharmaceutical compositions containing borate-polyol complexes |
Jun, 2030
(6 years from now) | |
| US9044484 | ALCON LABS INC | Aqueous pharmaceutical compositions containing borate-polyol complexes |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Apr 19, 2016 |
Market Authorisation Date: 19 April, 2013
Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension
Dosage: SUSPENSION/DROPS;OPHTHALMIC
How can I launch a generic of SIMBRINZA before it's drug patent expiration?
More Information on Dosage
SIMBRINZA family patents
